TH77076A - Pharmaceutical formulation mixtures - Google Patents
Pharmaceutical formulation mixturesInfo
- Publication number
- TH77076A TH77076A TH301002718A TH0301002718A TH77076A TH 77076 A TH77076 A TH 77076A TH 301002718 A TH301002718 A TH 301002718A TH 0301002718 A TH0301002718 A TH 0301002718A TH 77076 A TH77076 A TH 77076A
- Authority
- TH
- Thailand
- Prior art keywords
- mixture
- hmg
- cholesterol
- lactose
- pharmaceutical formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 2
- 239000003529 anticholesteremic agent Substances 0.000 abstract 2
- 229960005070 ascorbic acid Drugs 0.000 abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 abstract 2
- 239000011668 ascorbic acid Substances 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 235000010980 cellulose Nutrition 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 235000019359 magnesium stearate Nutrition 0.000 abstract 2
- 239000007800 oxidant agent Substances 0.000 abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
Abstract
DC60 (29/09/46) สารผสมนี้ทำให้มีสารผสมทางเภสัชกรรมที่ประกอบด้วยสารยับยั้งการดูดซึม โคเลสเตอรอลและสารยับยั้ง HMG-CoA รีดัคเทส, สารต่อต้านการออกซิไดซ์หนึ่งชนิด หรือมากกว่า, เซลลูโลสผลึกละเอียด, ไฮดรอกซีโปรปิลเมทธิลเซลลูโลส, แมกนีเซียมสเตียเรท และแลคโตส สารผสมไม่จำเป็นต้องประกอบด้วยกรดแอสคอร์บิคเพื่อที่จะให้ได้ความเสถียร ที่พึงประสงค์ สารผสมนี้ทำให้มีสารผสมทางเภสัชกรรมที่ประกอบด้วยสารยับยั้งการดูดซึม โคเลสเตอรอลและสารยับยั้ง HMG-CoA รีดัคเทส, สารต่อต้านการออกซิไดซ์หนึ่งชนิด หรือมากกว่า, เซลลูโลสผลึกละเอียด, ไฮดรอกซีโปรปิลเมทธิลเซลลูโลส, แมกนีเซียมสเตียเรท และแลคโตส สารผสมไม่จำเป็นต้องประกอบด้วยกรดแอสคอร์บิคเพื่อที่จะได้ความเสถียร ที่พึงประสงค์ สิทธิบัตรยา DC60 (29/09/46) This mixture contains a pharmaceutical ingredient containing an absorption inhibitor. Cholesterol and HMG-CoA reductase inhibitors, one or more anti-oxidizing agents, fine crystalline cellulose, hydroxypropyl methyl cellulose, magnesium stearate, and lactose. Mixture does not need to contain ascorbic acid in order to be stable. Desirable This mixture contains a pharmaceutical mixtures containing absorption inhibitors. Cholesterol and HMG-CoA reductase inhibitors, one or more anti-oxidizing agents, fine crystalline cellulose, hydroxypropyl methyl cellulose, magnesium stearate, and lactose. Mixture does not need to contain ascorbic acid in order to be stable. Desirable drug patent
Claims (3)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH77076A true TH77076A (en) | 2006-04-20 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040588A1 (en) | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE | |
| WO2006135723A3 (en) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | |
| WO2005034908A3 (en) | A solid dosage form comprising a fibrate and a statin | |
| CO5630034A2 (en) | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS | |
| WO2004033431A3 (en) | Hydroxypyrazoles for use against metabolic-related disorders | |
| DE60239425D1 (en) | CALCIUMATOR VASTATIN CONTAINING MEDICINE PREORMULATION | |
| RU2002134764A (en) | STABILIZED PHARMACEUTICALLY EFFECTIVE COMPOSITION AND PHARMACEUTICAL DRUG CONTAINING IT | |
| WO2003080070A3 (en) | Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer | |
| WO2004096134A3 (en) | Substituted 1,4-diazepines and uses thereof | |
| NO20024040L (en) | New malonic acid derivatives, processes for their preparation, their use as an inhibitor of factor XA activity, and pharmaceutical compounds containing this | |
| IL164699A (en) | Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient | |
| WO2002100886A8 (en) | Pyrrolidin-2-one derivatives as inhibitors of factor xa | |
| EP1386606A4 (en) | STABLE INJECTION PRODUCT AT HIGH CONCENTRATIONS CONTAINING A PYRAZOLONE DERIVATIVE | |
| PE20060771A1 (en) | GEMCITABIN AMIDE PROPHARMAC AND COMPOSITIONS CONTAINING IT | |
| MXPA02012889A (en) | 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof. | |
| WO2005065639A3 (en) | Novel pharmaceutical compositions | |
| JP5765738B2 (en) | Rosuvastatin and atorvastatin derivatives | |
| TH77076A (en) | Pharmaceutical formulation mixtures | |
| WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
| WO2000059448A3 (en) | Association of no-synthase inhibitor(s) and metabolic antioxidant(s) | |
| AU2003256108A1 (en) | Organic acid salt of amlodipine | |
| WO2005051937A8 (en) | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof | |
| WO2007071012A8 (en) | Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor | |
| EP1852119A4 (en) | PHARMACEUTICAL PREPARATION CONTAINING PHENOXAZINIUM DERIVATIVE AS ACTIVE INGREDIENT | |
| WO2007059952A3 (en) | 1-benzazepine-3-sulfonylamino-2-pyrrloridones as factor xa inhibitors |